சாந்தா லூசியா அடித்தளம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சாந்தா லூசியா அடித்தளம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சாந்தா லூசியா அடித்தளம் Today - Breaking & Trending Today

Machine-learning improves the prediction of stroke recovery


 E-Mail
IMAGE: MRI-based techniques are used to determine the individual structural wiring of the brain (left) and the underlying connectome (middle). Features from this complex information is used to classify patients with.
view more 
Credit: F. Hummel (EPFL).
When blood flow to the brain is somehow reduced or restricted, a person can suffer what we know as a stroke (from ischemic stroke in medical jargon). Stroke is one of those conditions that seems fairly common. This isn t a misperception: just in Europe, there are over 1.5 million new cases each year.
Some strokes can be lethal, and when they re not they often result in serious damage to the victim s ability to move. In fact, stroke is one of the major causes of long-term disability today. Recovery can be a long and arduous road. Again, in Europe, under 15% of the patients achieve full recovery, leaving 3.7 million patients with persistent impairments. Clearly, this is a medical problem that ....

South Korea , Republic Of Korea , Friedhelm Hummel , Philippj Koch , School Of Life Sciences , University School Of Medicine Republic Korea , Santa Lucia Foundation , Geneva University Hospitals , Processing Laboratory , Centre Hospitalier Universitaire Vaudois , Sungkyunkwan University School Of Medicine Professor , University Of Geneva Medical School , University Of Lausanne Uni , Lausanne University Hospital , Sungkyunkwan University Republic Of Korea , Professor Friedhelm Hummel , Defitech Chair , Clinical Neuroengineering , Sungkyunkwan University School , University Medical School , Inserm Paris , Professor Thiran , University Hospital , Geneva Medical School , Hospitalier Universitaire Vaudois , University Hospitals ,

Italfarmaco Announces Topline Data from Phase 2 Trial with Givinostat in Patients with Becker Muscular Dystrophy


Posted on
8181
Italfarmaco Group announced today topline data from its proof-of-concept Phase 2 trial with Givinostat, the company’s proprietary histone deacetylase (HDAC) inhibitor, in 51 adult males with Becker Muscular Dystrophy (BMD). The study was designed to evaluate the effect of Givinostat in BMD, building on the experience developed in Duchenne Muscular Dystrophy. Based on this experience, change in total fibrosis in the muscle biopsy was selected as the primary endpoint of the study and change in fat fraction and contractile CSA using quantitative Magnetic Resonance Imaging (MRI) as key secondary endpoints. Givinostat did not show significant difference in the primary endpoint compared to placebo. However, significant difference from placebo in MRI of muscles in the whole thigh as well as quadriceps confirmed the ability of Givinostat to counteract muscle deterioration in the treated BMD patients. Th ....

San Diego , United States , Regione Lombardia , Paolo Bettica , Krista Vandenborne , European Regional Development Fund , Santa Lucia Foundation , University Of Florida , Department Of Physical Therapy , Regional Operational Program , Italfarmaco Group , Neurologist At Leiden University Medical Centre , University Of Milan , Becker Muscular Dystrophy , Duchenne Muscular , Magnetic Resonance Imaging , Parent Project Muscular Dystrophy , Muscular Dystrophy , Chief Medical Officer , Duchenne Muscular Dystrophy , Transfer Domain , Motor Function Measure , Adverse Events , Treatment Emergent Adverse Events , Principal Investigator , Physical Therapy ,